Fortress Biotech, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Fortress Biotech, Inc. (FBIO) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $1.90 million for the 12-month period ending 2013-12-31, per its 10-K filed 2016-03-15.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2016-03-15
- Fortress Biotech, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2013 was $1.90M, a 17.61% decline from fiscal 2012.
- Fortress Biotech, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2012 was $2.31M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month as first filed |
|---|---|---|
| 2013-12-31 | $1.90M 10-K · filed 2016-03-15 | -$1.90M 10-K · filed 2014-03-14 |
| 2012-12-31 | $2.31M 10-K · filed 2015-03-16 | -$1.00K 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |